Baxter launches swine flu vaccine

Celvapan is one of two vaccines now available for swine flu prophylaxis in high-risk patients.

Celvapan should be used in accordance with official guidance. The dose recommendations are based on safety and immunogenicity data available from the administration of a vaccine containing 7.5 microgram HA derived from A/Vietnam/1203/2004 (H5N1) in adults, including the elderly. Doses were given on days 0 and 21.

The decision to use Celvapan in each age group should take into account the extent of the clinical data available with the version containing H5N1 antigen and the disease characteristics of the current influenza pandemic.

View Celvapan drug record

Further information: Baxter


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases